5-Amino-1MQ Safety Questions: What Studies Report

The short version

Searches about 5-Amino-1MQ and the liver, kidneys, or long-term tolerability run into a simple problem: the published record on this compound and on nicotinamide N-methyltransferase (NNMT) inhibition generally is preclinical. The verified studies below were conducted in cultured human cancer cells, in diet-induced obese (DIO) mice, and in urothelial bladder cancer models. They reported target biology, anti-proliferative activity and microbiome composition — not hepatic enzyme panels, histopathology scores, or adverse-event tables from human volunteers. Where this page says no data exist, that reflects the scope of the papers cited, and it is stated plainly rather than filled in with inference.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. It is also not legal advice.

What the compound is, as described in the literature: What Studies Report

5-Amino-1MQ (5-amino-1-methylquinolinium) belongs to a class of small molecules developed to inhibit NNMT. Researchers working on cervical cancer cells described a small-molecule NNMT inhibitor and reported anti-proliferative activity in HeLa cells, framing NNMT as a druggable enzyme rather than a nutritional supplement target. Separately, a 2024 report characterised NNMT as a NAD(+) metabolism enzyme and examined its role in cancer-associated fibroblasts. Those two framings — an enzyme in NAD(+) handling, and an enzyme whose inhibition slows proliferation of certain cancer cells — set the boundaries of what the safety conversation can honestly draw on.

Liver questions: What Studies Report

This is the most common search around the compound, so it deserves an unambiguous answer. None of the verified studies reported liver enzyme measurements, bilirubin, hepatic histopathology, or hepatotoxicity signals in any species. The mouse work available here focused on gut microbial composition under a combined dietary and pharmacological intervention, with researchers reporting that a reduced calorie diet combined with NNMT inhibition established a distinct microbiome in DIO mice. Liver-specific endpoints were not the reported subject of that work.

That absence is not the same as a clean bill of health, and it is not the same as evidence of harm. It means that anyone searching "5-Amino-1MQ side effects liver" is searching for a dataset that, in the peer-reviewed literature represented here, has not been published. Claims circulating outside the literature about hepatic safety — in either direction — do not trace back to these papers. The honest description is: unstudied in the sources verified for this page.

Why the liver question keeps coming up

NNMT sits in NAD(+)-related metabolism, and the 2024 bladder cancer paper explicitly described it as a NAD(+) metabolism enzyme in cancer-associated fibroblasts. Readers who know that NAD(+) and methyl-group handling are metabolically central reasonably ask what happens to organs with heavy metabolic traffic. The reasoning is sound; the data to answer it are not present. A mechanistic reason to ask a question is not a substitute for a study that answers it.

Animal findings: What Studies Report

The most directly relevant in-vivo work in the verified set is the 2022 DIO mouse study. Researchers combined a reduced calorie diet with NNMT inhibition and reported that the combination established a distinct microbiome compared with the comparator conditions. The reported outcome was compositional — which bacterial communities differed — rather than a toxicology readout.

What that study did not report, within the scope of its title and abstract, includes: mortality or morbidity attributable to the inhibitor, organ weights, clinical chemistry panels, behavioural observations, or a no-observed-adverse-effect level. Microbiome shifts are themselves biologically interesting — gut communities influence bile acid handling, short-chain fatty acid production and immune tone — but the study reported association with the intervention, not downstream clinical consequences. Extrapolating a microbiome difference in mice into a human safety statement would go well beyond what the authors published.

Cell and tumour-model findings: What Studies Report

Two of the verified papers concern cancer biology, and both cut in directions worth understanding.

In cervical cancer cells, researchers reported that a small-molecule NNMT inhibitor showed anti-proliferative activity in HeLa cells. In a tumour-microenvironment context, a 2024 study reported that NNMT in cancer-associated fibroblasts drove tumour progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer. Taken together, these describe NNMT as a target whose inhibition was investigated for anti-tumour purposes — the opposite framing from a compound suspected of driving cancer risk.

Two cautions follow. First, anti-proliferative activity in an immortalised cell line is a screening result, not a demonstration of safety or efficacy in an organism; cells in a dish lack liver metabolism, renal clearance and an intact immune system. Second, an enzyme that is important in tumour stroma is also present in normal tissue, and neither study reported systematic assessment of normal-tissue consequences of inhibition. The cancer literature clarifies why researchers are interested in NNMT; it does not substitute for safety pharmacology.

Human safety data: What Studies Report

No human clinical trial of 5-Amino-1MQ appears in the verified literature for this page. That means there is no published human information on:

• tolerated dose ranges, single or repeated
• pharmacokinetics, half-life, or clearance route in people
• liver, kidney, cardiac or haematological laboratory monitoring
• frequency or severity of any adverse event
• interactions with prescription medicines, alcohol, or other supplements
• effects over any duration of continued exposure

Where a compound has cell-line and rodent data but no human trial, the standard scientific position is that its human safety profile is undefined, not "probably fine because animals tolerated it." The DIO mouse study reported a microbiome outcome under a specific combined intervention in mice; species differences in metabolism, gut flora and dose scaling make that a poor basis for human inference.

Populations, contraindications and interactions: What Studies Report

The verified papers contain no data on pregnancy or lactation, paediatric exposure, older adults, people with existing liver or kidney impairment, people with cancer histories, or people taking any concomitant medication. No contraindication list has been published for this compound in these sources, because no clinical programme generating one appears in them.

The oncology findings do highlight one area where researchers themselves flagged context-dependence: NNMT activity was reported to influence macrophage behaviour and immunotherapy resistance in bladder cancer, meaning the enzyme intersects with immune signalling in at least one disease model. Whether inhibition alters immune function in a healthy organism was not addressed in these papers.

The evidence at a glance

How researchers describe the open questions

Reading these three papers together, the unresolved items are structural rather than incidental:

1. No dose-ranging toxicology in the verified record. Without published no-observed-adverse-effect levels, there is no evidentiary anchor for any human exposure figure.
2. Organ-specific endpoints unmeasured. Liver, kidney and cardiac readouts were not the reported focus of any of the three studies.
3. Microbiome shifts observed but not followed clinically. Researchers reported a distinct microbiome in treated DIO mice; the health consequences of that shift were not the reported outcome.
4. Target is context-dependent. NNMT inhibition was explored as anti-tumour in two settings — cervical cancer cells and bladder tumour stroma — leaving normal-tissue consequences of chronic inhibition as an open question.
5. No human bridge. Nothing in the verified set translates rodent or cell results into human pharmacology.

Regulatory context

There is no approved human drug product containing 5-Amino-1MQ. Material offered under research-use-only (RUO) labelling is, by that labelling, not intended for human administration, and RUO status does not imply that a safety review has occurred. Compounds without an approved application have not undergone the review of manufacturing, purity, labelling and clinical safety that approval requires. Regulatory status is described here as a matter of fact; this is not legal advice, and rules differ by jurisdiction and change over time.

Reading safety claims critically

A few habits help when comparing marketing language with the literature. Claims should name a study, a model and an endpoint — "well tolerated" without a species, duration and measured variable is not a finding. Cell-line results such as the HeLa anti-proliferative report describe what happened to cells in culture. Mouse results such as the DIO microbiome study describe what happened in mice under a specific combined intervention. Neither describes what happens in a person, and neither should be cited as if it did.

Again: this page is for educational purposes only and is not medical advice; consult a licensed physician about any question concerning liver health, medication interactions or the use of any substance.

References

• NAD(+) metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer (Journal for ImmunoTherapy of Cancer, 2024)
• Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells (Journal of Obstetrics and Gynaecology, 2021)
• Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice (Scientific Reports, 2022)